• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Tsutomu Hara, David Cameron-Smith, Gregory J. Cooney, M. Kusunoki, Kazuhiko Tsutsumi, Len H. Storlien
  • Biology, Medicine
  • Metabolism: clinical and experimental
  • 1998 (First Publication: 1 February 1998)
  • High circulating fasting and prandial triglyceride levels are associated with both insulin resistance and the development of cardiovascular disease. The aim of this investigation was to study theExpand
  • Masataka Kusunoki, Kazuhiko Tsutsumi, +8 authors Yutaka Nakaya
  • Biology, Medicine
  • Metabolism: clinical and experimental
  • 2002 (First Publication: 1 June 2002)
  • Insulin resistance results in accumulation of triglyceride content and reduction of glycogen content in skeletal muscle. However, very few studies have measured lipid content and glycogen content inExpand
  • Jiro Nakamura, Naoki Koh, +11 authors Nigishi Hotta
  • Chemistry, Medicine
  • The Journal of pharmacology and experimental…
  • 1998 (First Publication: 1 December 1998)
  • To investigate the relationship between polyol pathway hyperactivity and altered carnitine metabolism in the pathogenesis of diabetic neuropathy, the effects of an aldose reductase inhibitor,Expand
  • Masataka Kusunoki, Kazuhiko Tsutsumi, Tsutomu Hara, Hitoshi Ogawa, Yutaka Nakaya
  • Medicine, Biology
  • Experimental Gerontology
  • 2002 (First Publication: 1 July 2002)
  • Exercise decreases plasma total cholesterol and triglycerides, and simultaneously, increases high density lipoprotein (HDL) cholesterol. As a result, exercise is believed to aid in preventingExpand
  • Masataka Kusunoki, Kazuhiko Tsutsumi, +13 authors Yutaka Nakaya
  • Chemistry, Medicine
  • Metabolism: clinical and experimental
  • 2004 (First Publication: 1 February 2004)
  • NO-1886 is a lipoprotein lipase (LPL) activator. Administration of NO-1886 results in an increase in plasma high-density lipoprotein cholesterol (HDL-C) and a decrease in plasma triglyceride (TG)Expand